Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Nutrients ; 13(5)2021 May 13.
Article in English | MEDLINE | ID: mdl-34068047

ABSTRACT

Adverse food reactions include immune-mediated food allergies and non-immune-mediated intolerances. However, this distinction and the involvement of different pathogenetic mechanisms are often confused. Furthermore, there is a discrepancy between the perceived vs. actual prevalence of immune-mediated food allergies and non-immune reactions to food that are extremely common. The risk of an inappropriate approach to their correct identification can lead to inappropriate diets with severe nutritional deficiencies. This narrative review provides an outline of the pathophysiologic and clinical features of immune and non-immune adverse reactions to food-along with general diagnostic and therapeutic strategies. Special emphasis is placed on specific nutritional concerns for each of these conditions from the combined point of view of gastroenterology and immunology, in an attempt to offer a useful tool to practicing physicians in discriminating these diverging disease entities and planning their correct management. We conclude that a correct diagnostic approach and dietary control of both immune- and non-immune-mediated food-induced diseases might minimize the nutritional gaps in these patients, thus helping to improve their quality of life and reduce the economic costs of their management.


Subject(s)
Food Hypersensitivity/physiopathology , Food Intolerance/physiopathology , Nutritional Status , Diet Therapy/adverse effects , Diet Therapy/methods , Food/adverse effects , Food Hypersensitivity/diagnosis , Food Hypersensitivity/immunology , Food Hypersensitivity/therapy , Food Intolerance/diagnosis , Food Intolerance/immunology , Food Intolerance/therapy , Humans
2.
Obes Surg ; 29(10): 3195-3201, 2019 10.
Article in English | MEDLINE | ID: mdl-31077026

ABSTRACT

INTRODUCTION: Food intolerance is expected during the postoperative period following gastric bypass and may be associated with inadequate chewing. OBJECTIVE: To evaluate chewing before and after speech therapy intervention in subjects undergoing Roux-en-Y gastric bypass who present with food intolerance. MATERIALS AND METHODS: This was a randomized controlled trial, approved by the Brazilian Ethics and Research Committee under n. 438,600. The study population was allocated into two groups: the study group (SG), who received speech therapy intervention, and the control group (CG), who did not receive any intervention, in six visits at 7, 15, 30, 60, and 90 days (v7, v15, v30, v60, and v90) after the initial visit (v0). During v0 and v90, a chewing evaluation was performed according to the MBGR protocol adapted. The significance level adopted was 5%. RESULTS: A total of 30 females (88%) and 4 males (12%) were analyzed. The SG had 18 subjects, and the CG had 16, with mean ages of 50.17 ± 12.28 years and 45.69 ± 9.78 years, respectively. The postoperative time ranged from 4 to19 months. In the SG, a marked improvement in the number of episodes of food intolerance was observed (p < 0.001), an improvement in the intake of cereals and meats (p = 0.004 and p < 0.001, respectively), and an improvement in chewing capacity and swallowing (p = 0.002 and p = 0.011, respectively). CONCLUSION: Speech therapy intervention in chewing led to a marked improvement of food acceptance and food intolerance resulting from Roux-en-Y gastric bypass.


Subject(s)
Food Intolerance/etiology , Gastric Bypass/adverse effects , Mastication/physiology , Obesity, Morbid/surgery , Speech Therapy/methods , Adult , Aged , Deglutition/physiology , Diet , Female , Food Intolerance/diagnosis , Food Intolerance/physiopathology , Food Intolerance/therapy , Gastric Bypass/methods , Humans , Male , Middle Aged , Postoperative Period
3.
J Neonatal Perinatal Med ; 12(3): 295-300, 2019.
Article in English | MEDLINE | ID: mdl-30883365

ABSTRACT

BACKGROUND: The efficacy of macrolide treatment on gastrointestinal motility and acquirement of feeding tolerance in extremely low birth weight (ELBW) infants are controversial. This study aimed to evaluate clinical effects of parenterally administered erythromycin (EM) and clarithromycin (CAM) on gastrointestinal motility in ELBW infants. METHODS: ELBW infants treated in Tokyo Medical University Hospital were retrospectively studied. Several outcomes of ELBW infants treated with EM or CAM were compared with those recognized before initiation of the medication, as well as with those of patients with no macrolide treatment. The primary outcomes included average gastric residual volume that was evaluated 3 hours after enteral feeding. Secondary outcomes were the number of patients who developed feeding intolerance, stool frequency, and other adverse events, such as respiratory comorbidities and pyloric stenosis. RESULTS: Among a total of 53 infants, 20 and 13 were treated with EM and CAM, respectively, whereas 20 infants were not administered macrolides. The gastric residual volume was significantly decreased after initiation of medication compared with before medication in the EM group, whereas that of the untreated group showed no change. When the EM and CAM groups were combined, the gastric residual volume was also significantly decreased after treatment compared with before treatment. An increase in stool frequency and pyloric stenosis were not observed in the groups. CONCLUSION: EM might be effective for acquiring feeding tolerance in ELBW infants. A future prospective study with a larger population is required to determine the efficacy of CAM.


Subject(s)
Clarithromycin/administration & dosage , Erythromycin/administration & dosage , Gastrointestinal Agents/administration & dosage , Gastrointestinal Motility/drug effects , Infant, Extremely Low Birth Weight/physiology , Clarithromycin/pharmacology , Enteral Nutrition/methods , Erythromycin/pharmacology , Female , Food Intolerance/congenital , Food Intolerance/physiopathology , Gastrointestinal Agents/pharmacology , Humans , Infant, Newborn , Infant, Premature , Male , Retrospective Studies , Treatment Outcome
4.
Adv Exp Med Biol ; 1125: 49-56, 2019.
Article in English | MEDLINE | ID: mdl-30656551

ABSTRACT

Colic is a common and distressing functional gastrointestinal disorder during infancy. It is a behavioral phenomenon in infants aged 1-4 months involving prolonged inconsolable crying and agitated status with multifactorial etiology. Colic can be considered as a benign, self-limited process because the baby normally grows and feeds even with transient irritable mood. Nevertheless, infantile colic is a common difficulty causing anxiety during parenthood and a recurrent reason for them to seek medical help, especially if it is the first child. The causes of colic can be classified as non-gastrointestinal or gastrointestinal. The former includes altered feeding techniques, modified child-parent relationship, immaturity of central nervous system, behavioral etiology, and maternal smoking or nicotine replacement therapy. Instead, the latter involves inadequate production of lactase enzyme, cow's milk protein intolerance, alteration of intestinal microbiota, gastrointestinal immaturity, or inflammation which causes intestinal hyperperistalsis due to increase in serotonin secretion and motilin receptor expression.Probiotics may play a crucial part in the manipulation of the microbiota. Probiotic administration is likely to maintain intestinal homeostasis through the modulation of permeability and peristalsis, influencing the gut-brain axis and inhibiting hypersensitivity. This is a decisive field in the development of preventive and therapeutic strategies for infantile colic. However, further studies are needed for each specific formulation in order to better characterize pharmacodynamic and pharmacokinetic properties and to evaluate their application as a possible preventive strategy if administered early during infancy against the later development of pain-related FGIDs.


Subject(s)
Colic/prevention & control , Colic/therapy , Gastrointestinal Microbiome , Probiotics/therapeutic use , Colic/etiology , Food Intolerance/physiopathology , Humans , Infant
5.
Arq. gastroenterol ; 55(4): 417-422, Oct.-Dec. 2018.
Article in English | LILACS | ID: biblio-983839

ABSTRACT

ABSTRACT Approximately 80% of irritable bowel syndrome (IBS) patients report that their symptoms are triggered after ingesting one or specific food groups. Gluten, wheat and related proteins (e.g., amylase-trypsin inhibitors, and fermentable oligo-di-mono-saccharides and polyols (FODMAPs) are the most relevant IBS symptom triggers, although the true 'culprit(s)' is/are still not well established. The concept of causal relationship between gluten intake and the occurrence of symptoms in the absence of celiac disease and wheat allergy was termed non-celiac gluten sensitivity (NCGS). The borderline between celiac disease, wheat allergy, IBS and NCGS is not always clearly distinguishable, and the frequency and clinical identity of NGCS are still unclear. An overlap between IBS and NCGS has been detected. The incomplete knowledge of the etiopathogenesis of these clinical conditions, lack of data on their real epidemiology, as well as the absence of a gold standard for their diagnosis, make the overall picture difficult to understand "It is crucial to well define the interaction between IBS, food intolerance and NGCS, since the role of diet in IBS and its dietary management is an essential tool in the treatment of a large number of these patients". The objective of the present review is to provide an overview highlighting the interaction between IBS, food intolerance and NCGS in order to unravel whether gluten/wheat/FODMAP sensitivity represents 'facts' and not 'fiction' in IBS symptoms.


RESUMO Cerca de 80% dos pacientes com síndrome do intestino irritável (SII) relatam que seus sintomas são desencadeados após a ingestão de um ou grupos específicos de alimentos. Nesse grupo, glúten, trigo e proteínas relacionadas (como inibidores de amilase-tripsina e oligo-di-mono-sacarídeos e polióis fermentáveis (FODMAPs) são os fatores desencadeantes de sintomas mais relevantes da SII, embora o verdadeiro 'culpado(s)' ainda não seja conhecido. O conceito de relação causal entre a ingestão de glúten e a ocorrência de sintomas na ausência de doença celíaca e alergia ao trigo foi denominado sensibilidade ao glúten não celíaca (SGNC). A fronteira clínica entre doença celíaca, alergia ao trigo, SII e SGNC não está claramente distinguível, apesar da sobreposição entre SII e SGNC ser frequentemente relatada na literatura. O conhecimento incompleto da etiopatogenia dessas condições clínicas, a falta de dados sobre sua epidemiologia real, bem como a ausência de um padrão ouro para seu diagnóstico da associação SII/SGNC, dificultam a compreensão dessa nova entidade. "É de suma importância definir com precisão a interação entre SII, intolerância alimentar e SGNC, já que o papel da dieta no tratamento da SII é uma ferramenta essencial no tratamento de um grande número desses pacientes". A presente revisão tem como objetivo apresentar dados atuais a respeito da interação entre SII, intolerância alimentar e SGNC. Além disso questiona-se, com os dados disponíveis, a sensibilidade ao glúten/trigo/FODMAPs, representa "fato" e não "ficção" na geração de sintomas associados a SII.


Subject(s)
Humans , Celiac Disease/physiopathology , Irritable Bowel Syndrome/physiopathology , Food Intolerance/physiopathology
6.
Nutrients ; 10(3)2018 Mar 12.
Article in English | MEDLINE | ID: mdl-29534502

ABSTRACT

We have previously reported that 60% sucrose diet-fed ChREBP knockout mice (KO) showed body weight loss resulting in lethality. We aimed to elucidate whether sucrose and fructose metabolism are impaired in KO. Wild-type mice (WT) and KO were fed a diet containing 30% sucrose with/without 0.08% miglitol, an α-glucosidase inhibitor, and these effects on phenotypes were tested. Furthermore, we compared metabolic changes of oral and peritoneal fructose injection. A thirty percent sucrose diet feeding did not affect phenotypes in KO. However, miglitol induced lethality in 30% sucrose-fed KO. Thirty percent sucrose plus miglitol diet-fed KO showed increased cecal contents, increased fecal lactate contents, increased growth of lactobacillales and Bifidobacterium and decreased growth of clostridium cluster XIVa. ChREBP gene deletion suppressed the mRNA levels of sucrose and fructose related genes. Next, oral fructose injection did not affect plasma glucose levels and liver fructose contents; however, intestinal sucrose and fructose related mRNA levels were increased only in WT. In contrast, peritoneal fructose injection increased plasma glucose levels in both mice; however, the hepatic fructose content in KO was much higher owing to decreased hepatic Khk mRNA expression. Taken together, KO showed sucrose intolerance and fructose malabsorption owing to decreased gene expression.


Subject(s)
Dietary Sugars/adverse effects , Dysbiosis/etiology , Food Intolerance/physiopathology , Fructose/adverse effects , Malabsorption Syndromes/physiopathology , Nuclear Proteins/metabolism , Sucrose/adverse effects , Transcription Factors/metabolism , Animals , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Bifidobacterium/drug effects , Bifidobacterium/growth & development , Bifidobacterium/isolation & purification , Cecum/drug effects , Cecum/metabolism , Cecum/microbiology , Cecum/pathology , Clostridium/drug effects , Clostridium/growth & development , Clostridium/isolation & purification , Dietary Sugars/metabolism , Dysbiosis/microbiology , Food Intolerance/etiology , Food Intolerance/metabolism , Food Intolerance/pathology , Fructokinases/chemistry , Fructokinases/genetics , Fructokinases/metabolism , Fructose/administration & dosage , Fructose/metabolism , Gastrointestinal Microbiome/drug effects , Gene Expression Regulation/drug effects , Glycoside Hydrolase Inhibitors/pharmacology , Injections, Intraperitoneal , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestinal Mucosa/microbiology , Intestinal Mucosa/pathology , Intestines/drug effects , Intestines/microbiology , Intestines/pathology , Lactobacillales/drug effects , Lactobacillales/growth & development , Lactobacillales/isolation & purification , Liver/drug effects , Liver/metabolism , Liver/pathology , Malabsorption Syndromes/etiology , Malabsorption Syndromes/metabolism , Malabsorption Syndromes/pathology , Male , Mice, Inbred C57BL , Mice, Knockout , Nuclear Proteins/genetics , Organ Size/drug effects , Transcription Factors/genetics
7.
J Med Food ; 21(3): 207-214, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29315017

ABSTRACT

Nonceliac gluten sensitivity (NCGS) is a gluten-related gastrointestinal disorder distinct from celiac disease (CD) and gluten allergy that is not easy to diagnose due to the lack of biomarkers. It is characterized by intestinal symptoms and extraintestinal manifestations with the consumption of gluten-containing foods. In contrast to CD, NCGS patients do not present a genetic predisposition or intestinal villi atrophy. Recent studies question the proinflammatory triggering activity of α-gliadin fraction contained in wheat, since it has been demonstrated that the amylase-trypsin inhibitors (ATIs) exert a strong activating effect on the innate immune response. We aimed to analyze the role of ATIs in the activation of innate immunity and in the development of the symptoms characteristic of NCGS. A systematic literature search was made using databases such as MEDLINE, SciELO, Science Direct, and Scopus, with focus on key words such as "amylase-trypsin inhibitors," "wheat," "gluten," and "celiac." Many studies are available on the structure, inhibition mechanism, and immune system effects of ATIs, mainly focused on IgE-mediated reactions. Recently, with the increase of NCGS interest, has increased the literature on the capacity of ATIs contained in wheat to activate the innate immune system. Literature published to date questions the relationship between activation of the innate immune system and gluten in NCGS. ATIs may have acted as interfering contaminant of gluten and appear as potential activator of innate immunity in NCGS patients. In view of their potential impact, more interventional studies are needed to demonstrate the proinflammatory effect of ATIs.


Subject(s)
Edible Grain/adverse effects , Enzyme Inhibitors/adverse effects , Food Intolerance/etiology , Glutens/adverse effects , Plant Proteins/adverse effects , Trypsin Inhibitors/adverse effects , alpha-Amylases/antagonists & inhibitors , Animals , Edible Grain/chemistry , Enzyme Inhibitors/analysis , Enzyme Inhibitors/metabolism , Food Intolerance/immunology , Food Intolerance/metabolism , Food Intolerance/physiopathology , Glutens/metabolism , Hordeum/adverse effects , Hordeum/chemistry , Humans , Immunity, Innate , Immunity, Mucosal , Intestinal Mucosa/enzymology , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Plant Proteins/analysis , Plant Proteins/metabolism , Secale/adverse effects , Secale/chemistry , Toll-Like Receptors/agonists , Toll-Like Receptors/metabolism , Triticum/adverse effects , Triticum/chemistry , Trypsin Inhibitors/analysis , Trypsin Inhibitors/metabolism
8.
Ann Nutr Metab ; 73 Suppl 4: 18-28, 2018.
Article in English | MEDLINE | ID: mdl-30783041

ABSTRACT

Eosinophilic gastrointestinal diseases (EGIDs) comprise a group of chronic, inflammatory diseases of the gastrointestinal (GI) tract, that are characterized, clinically, by symptoms related to the dysfunction of the involved segment(s) of the GI tract, and histologically, by dense eosinophilic inflammation, in the absence of an identifiable secondary cause. The group of EGIDs comprises eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC). EoE is the most common and the best described EGID compared to EG, EGE, and EC. The clinical presentation of the EGIDs differs depending on the location and the extent of the eosinophilic infiltration in the GI tract, as well as its depth through the bowel wall. In the absence of biological markers, the diagnosis is based on the combination of clinical symptoms with the histological features of EGIDs, after the exclusion of secondary causes of eosinophilic inflammation of the GI tract. Treatment is individualized and includes elimination diets (mainly empiric or elemental) and/or drugs, according to the involved GI segment: proton pump inhibitors or local steroids in EoE; local or oral systemic steroids in EG/EGE limited to the duodenum; oral systemic steroids in EGE with lower small intestine and/or colon involvement. In patients with EoE, maintenance treatment with lower doses may be considered following histological remission with the means of drugs. In patients treated with elimination diets, disease food triggers identified during food reintroduction need to be further eliminated. Esophageal stenosis despite medical treatment requires endoscopic dilation, while the use of thiopurines or anti-TNF drugs may be considered in refractory or steroid-dependent EGID (other than EoE). The aim of this review is to provide the available evidence on each of the above disorders, to aid clinicians to interpret the clinical manifestations and the laboratory findings and choose the best available treatment option.


Subject(s)
Enteritis/diagnosis , Eosinophilia/diagnosis , Eosinophilic Esophagitis/diagnosis , Gastritis/diagnosis , Gastrointestinal Tract/physiopathology , Colitis/diagnosis , Colitis/physiopathology , Colitis/therapy , Diagnosis, Differential , Enteritis/physiopathology , Enteritis/therapy , Eosinophilia/physiopathology , Eosinophilia/therapy , Eosinophilic Esophagitis/physiopathology , Eosinophilic Esophagitis/therapy , Food Intolerance/diagnosis , Food Intolerance/physiopathology , Gastritis/physiopathology , Gastritis/therapy , Humans , Inflammation
9.
Arq Gastroenterol ; 55(4): 417-422, 2018.
Article in English | MEDLINE | ID: mdl-30785529

ABSTRACT

Approximately 80% of irritable bowel syndrome (IBS) patients report that their symptoms are triggered after ingesting one or specific food groups. Gluten, wheat and related proteins (e.g., amylase-trypsin inhibitors, and fermentable oligo-di-mono-saccharides and polyols (FODMAPs) are the most relevant IBS symptom triggers, although the true 'culprit(s)' is/are still not well established. The concept of causal relationship between gluten intake and the occurrence of symptoms in the absence of celiac disease and wheat allergy was termed non-celiac gluten sensitivity (NCGS). The borderline between celiac disease, wheat allergy, IBS and NCGS is not always clearly distinguishable, and the frequency and clinical identity of NGCS are still unclear. An overlap between IBS and NCGS has been detected. The incomplete knowledge of the etiopathogenesis of these clinical conditions, lack of data on their real epidemiology, as well as the absence of a gold standard for their diagnosis, make the overall picture difficult to understand "It is crucial to well define the interaction between IBS, food intolerance and NGCS, since the role of diet in IBS and its dietary management is an essential tool in the treatment of a large number of these patients". The objective of the present review is to provide an overview highlighting the interaction between IBS, food intolerance and NCGS in order to unravel whether gluten/wheat/FODMAP sensitivity represents 'facts' and not 'fiction' in IBS symptoms.


Subject(s)
Celiac Disease/physiopathology , Food Intolerance/physiopathology , Irritable Bowel Syndrome/physiopathology , Humans
10.
Ann Nutr Metab ; 68 Suppl 1: 8-17, 2016.
Article in English | MEDLINE | ID: mdl-27355647

ABSTRACT

Childhood functional gastrointestinal disorders (FGIDs) affect a large number of children throughout the world. Carbohydrates (which provide the majority of calories consumed in the Western diet) have been implicated both as culprits for the etiology of symptoms and as potential therapeutic agents (e.g., fiber) in childhood FGIDs. In this review, we detail how carbohydrate malabsorption may cause gastrointestinal symptoms (e.g., bloating) via the physiologic effects of both increased osmotic activity and increased gas production from bacterial fermentation. Several factors may play a role, including: (1) the amount of carbohydrate ingested; (2) whether ingestion is accompanied by a meal or other food; (3) the rate of gastric emptying (how quickly the meal enters the small intestine); (4) small intestinal transit time (the time it takes for a meal to enter the large intestine after first entering the small intestine); (5) whether the meal contains bacteria with enzymes capable of breaking down the carbohydrate; (6) colonic bacterial adaptation to one's diet, and (7) host factors such as the presence or absence of visceral hypersensitivity. By detailing controlled and uncontrolled trials, we describe how there is a general lack of strong evidence supporting restriction of individual carbohydrates (e.g., lactose, fructose) for childhood FGIDs. We review emerging evidence suggesting that a more comprehensive restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) may be effective. Finally, we review how soluble fiber (a complex carbohydrate) supplementation via randomized controlled intervention trials in childhood functional gastrointestinal disorders has demonstrated efficacy.


Subject(s)
Child Nutritional Physiological Phenomena , Dietary Carbohydrates/adverse effects , Evidence-Based Medicine , Food Intolerance/physiopathology , Gastrointestinal Diseases/etiology , Malabsorption Syndromes/etiology , Precision Medicine , Abdominal Pain/etiology , Abdominal Pain/prevention & control , Child , Diet, Carbohydrate-Restricted , Dietary Carbohydrates/metabolism , Dietary Fiber/therapeutic use , Dietary Supplements , Fermentation , Food Intolerance/diet therapy , Food Intolerance/metabolism , Food Intolerance/microbiology , Gastrointestinal Diseases/diet therapy , Gastrointestinal Diseases/microbiology , Gastrointestinal Diseases/physiopathology , Gastrointestinal Microbiome , Humans , Malabsorption Syndromes/diet therapy , Malabsorption Syndromes/microbiology , Malabsorption Syndromes/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...